Correlation of serum antigen and antibody concentration with clinical features in HIV infection

Maadhava Ellaurie, Arye Rubinstein

Abstract

Serum antigen and antibody values were studied in 164 infants and children infected perinatally with HIV. HIV antigens p17, p24, gp41, and gp120 were determined in sera by immunoblot and antigen capture assays. Lymphocyte blast transformation, serum immunoglobulins, and circulating immune complexes were also evaluated. Altogether 50 patients had HIV antigens measured: 31 (62%) patients had p17 antigen in the serum and 29 (58%) had p24 antigen present. In 19 (38%) and nine (18%) patients, respectively, gp120 and gp41 were detected. All four HIV antigens were detected in seven (14%) patients. There was a positive correlation between the concentration of each HIV antigen and clinical outcome. When sequential specimens were analysed, 120 (73%) patients had p24 antigen present.

Patients with stage P2B and P2D (Centers for Disease Control classification) had the highest concentrations of p24 antigen with a mean of approximately 200 pg/ml. Altogether 70% of patients with a p24 antigen concentration of >30 pg/ml eventually died or had severe clinical disease within six to 24 months. Infants under 15 months of age with a p24 antigen concentration as low as 5 pg/ml also did poorly. Increased immunoglobulins and decreases in mitogenic responses and absolute CD4+ lymphocyte counts were more prevalent in patients with raised p24 antigen. Raised concentrations of circulating immune complexes were seen in the symptomatic phase of the disease whereas in the terminal stage of the disease raised serum antigen and a decrease in circulating immune complexes and absolute CD4+ lymphocyte count were evident. Loss of p24 and/or p17 antibody as well as a decreasing ELISA optical density for HIV antibody also signalled progression of the disease.

HIV is associated with clinical and immunological abnormalities.¹⁻³ Previous studies in adults indicated that HIV antigenaemia was associated with progressive clinical disease.⁴⁻¹⁰ Asymptomatic adults with persistent HIV antigenaemia are at increased risk of developing AIDS or AIDS related complex.¹¹ In the first few months of life the presence of HIV antigen is thought to be indicative of active disease as HIV antibody could be acquired passively from the mother.¹² In addition, raised and persistent serum antigen concentrations occur in a subset of children with symptomatic HIV infection

who do poorly (M Ellaurie *et al*, abstract presented at V International Conference on AIDS, Montreal, 1989).¹³⁻¹⁶

In the present study, we correlated HIV core and envelope antigenaemia with clinical and immunological abnormalities in a large cohort of HIV infected children.

Patients and methods

PATIENTS

One hundred and sixty two perinatally infected infants and children were studied at all stages of HIV infection classified according to the Centers for Disease Control (CDC), Atlanta, Georgia.¹⁷ Two additional patients were infected by transfusion of blood products. The ages of studied children ranged from 1 month to 11 years. The duration of follow up was six months to six years. Sequential determinations of serum antigen concentrations were obtained. In all patients HIV infection was confirmed by repeated serological tests, p24 antigenaemia, viral cultures and/or characteristic clinical symptoms.

Informed consent was obtained from the parents or guardians of the children studied. Human experimentation guidelines of the Albert Einstein College of Medicine were followed in the conduct of the clinical research.

LABORATORY TESTS

Serum immunoglobulins were determined by radial immunodiffusion (RID) using commercially available RID plates (Kallestad Labs).

Immunoblot assay for p17, gp41, and gp120 was done with nitrocellulose paper circles, 1 cm in diameter, that were washed in TRIS (trometamol) buffered saline (TBS), pH 7.5, dried, and placed individually into a 24 well culture plate (Gibco). Sera were absorbed onto the paper circles in two consecutive 2 µl additions and allowed to dry. Unreacted sites on the paper circles were blocked with 3% gelatin in TBS followed by washing with TBS containing 0.05% Tween 20. Mouse monoclonal antibodies against p17, gp41, and gp120 (DuPont Industries), diluted 1:5000 in TBS-1% gelatin, were reacted overnight with dot blots in 250 µl aliquots. After washing with TBS containing 0.05% Tween 20, goat antimouse IgG conjugated to horseradish peroxidase (Biorad Labs) at 1:2500-1:5000 dilution was added. After two hours incubation, 1-chloronaphthol containing hydrogen peroxide was added. The colour reaction was read within half an hour and scored from negative to 4+ according to colour intensity.

Albert Einstein
College of Medicine,
Department of
Pediatrics,
Bronx,
New York,
USA
Maadhava Ellaurie
Arye Rubinstein

Correspondence and requests
for reprints to:
Professor Maadhava Ellaurie,
310 Fullerton Avenue,
Newburgh,
New York 12550,
USA.

Accepted 8 August 1990

HIV p24 antigen was measured by a commercially available solid phase antigen capture enzyme linked immunosorbent assay (ELISA) (DuPont). A total of 250 serum samples from 164 patients were evaluated.

Mononuclear leucocytes were isolated from heparinised whole peripheral blood by sedimentation over Ficoll-Hypaque. Blast transformation of patients' lymphocytes was quantitated after stimulation with concanavalin A, pokeweed mitogen, phytohemagglutinin, and staphylococcus strain Cowan A as previously reported. CD4+ and CD8+ cells were quantitated by flow cytometry using an EPICS-C fluorescence activated cell sorter (Coulter Electronics) as previously reported.

HIV antibody was measured by a commercial ELISA and confirmed by western blot (Epi-tope).

CIQ assay for immune complexes—circulating immune complexes were measured by a commercial micro-ELISA procedure (Diamedix). Diluted serum specimens were added to goat CIQ coated wells. After incubation, the wells were washed and alkaline phosphatase conjugated antihuman IgG was added. After further washing the substrate p-nitrophenyl phosphate was added. The absorbance was read at 405 nm and results expressed as $\mu\text{g Eq/ml}$. Normal values were $<20 \mu\text{g Eq/ml}$.

Statistical analysis was performed by the Student's *t* test.

Results

Fifty patients were evaluated by the immunoblot and antigen capture assays for the presence of the following HIV antigens: p17, p24, gp41, and gp120 (table 1). Thirty one of the 50

patients (62%) demonstrated the presence of p17 antigen in the serum and 29 (58%) had p24 antigen detectable. In nine (18%) gp41 was detected in the serum and gp120 was found in 19 (38%). All four proteins (p17, p24, gp41, and gp120) were detected in seven of the 50 patients (14%).

Three patients who were p24 antigen negative were p17 positive by immunoblotting. Thirty four of 50 patients (68%) were p17 and p24 antigen positive and 36 (72%) had at least one antigen present in their sera (table 2).

Utilising the antigen capture assay, p24 antigenaemia was detected in 120 of 164 patients (73%) when sequential specimens were analysed.

In 60% of patients, p17 antibody was detected and p24 antibody was found in 92% of patients. All patients initially had the gp41 antibody and gp120 was found in 34% of patients.

Ninety per cent of all patients were hypergammaglobulinaemic and 82% had decreased mitogenic responses. The absolute CD4+ lymphocyte count was $<600/\times 10^6$ in 50% of patients. Circulating immune complexes were raised in 42 of 60 (70%) patients with a mean (SD) of 62 (70) $\mu\text{g Eq/ml}$. Patients with detectable serum antigen concentrations had higher serum immunoglobulin concentration compared with patients without detectable antigen (table 3). Decreases in mitogenic responses and absolute CD4+ lymphocyte counts were more prominent in patients with high serum antigen concentrations.

Three distinct phases of HIV infection were noted (figure). In the initial phase concentrations of circulating immune complexes were low and p24 antigen was undetectable or in low concentration. This phase was seen in most patients with CDC stage P2A. In the second or symptomatic phase concentrations of circulating immune complexes were high, p24 antigen was detectable, and the patients were symptomatic. Most of the patients in CDC stage P2B and P2C fell into this category. In the accelerated phase of the disease, the ELISA for HIV antibody frequently became negative, there was a loss of p24 antibody, and circulating immune complexes and CD4+ lymphocyte concentrations became very low and HIV antigenaemia increased before death. Not all patients go through all three phases. The accelerated phase usually followed the initial and symptomatic phases but could be seen in isolation under 1 year of age when patients developed opportunistic infection like *Pneumocystis carinii* pneumonia and died. In the latter case, raised HIV antigen and low circulating immune complex concentrations were observed.

The presence of HIV antigen in the serum preceded other immunological abnormalities

Table 1 Serum antigen and antibody values in 50 children infected with HIV

	p17	p24	gp41	gp120
No (%) of patients positive for antigen	31 (62)	29 (58)	9 (18)	19 (38)
No (%) of patients positive for antibody	30 (60)	46 (92)	50 (100)	17 (34)
No (%) of patients positive for antigen and antibody	19 (38)	26 (52)	9 (18)	8 (16)

Table 2 Antigens measured by immunoblotting in 50 patients

HIV antigen	No (%) positive
p17	31 (62)
p24	29 (58)
gp41	9 (18)
gp120	19 (38)
p17+p24	34 (68)
gp41+gp120	20 (40)
p17 or p24+gp41 or gp120	36 (72)
p17+p24+gp41+gp120	7 (14)

Table 3 Correlation of serum p24 antigen with immunoglobulins, mitogenic responses, and absolute CD4+ lymphocyte count

	IgG	IgA	IgM	Depressed mitogenic responses	Absolute CD4+ lymphocyte count
Serum antigen positive (n=21)	2480 (740)	166 (220)	306 (520)	7/21 (33%)	1816 (1046)
Serum antigen negative (n=29)	3306 (380)	433 (383)	665 (540)	15/29 (52%)	326 (206)
p Value	<0.05	<0.05	<0.05	>0.05	<0.05

Results are mean (SD).

Circulating immune complexes (CIC) in $\mu\text{g Eq/ml}$, HIV p24 antigen in pg/ml , absolute CD4+ lymphocytes, ELISA optical density (OD), and HIV p24 antibody are depicted for one patient. Three phases of the illness are apparent: initial phase with minimal or no symptoms and low CIC, low p24 antigen, and high CD4+ T cells and ELISA OD; symptomatic phase with increased concentration of CIC, a rise of p24 antigen, and a decrease in CD4+ T cells; and accelerated phase with a further rise in p24 antigen and decreased CIC, CD4+ T cells, ELISA OD and loss of p24 antibody before death.

like reversed T4:T8 ratio, hypergammaglobulinaemia, and depression of mitogenic responses in 20 patients and these patients had a poor outcome.

Thirty two of 42 patients (76%) had detectable antigen under the age of 15 months. Twenty of these 32 patients died, 10 had progressive disease, and two had mild symptoms. Patients without or with low serum HIV antigens (1+) had mild symptoms and were clinically stable for 24 months. Patients with high HIV antigen concentration (all four proteins >2+) had more severe clinical disease. The HIV antigen concentrations also increased significantly for months after the development of opportunistic infection. In six patients, viral infections like herpes and varicella also increased HIV p24 antigen with a decrease noted after the acute phase of the infection.

All patients who had greater than 3+ HIV antigen concentration (all four proteins) had opportunistic infection, severe bacterial and viral infection, lymphoma, thrombocytopenia, and chronic pneumonitis. Ninety per cent of these patients died within six to 24 months.

In table 4, the serum p24 antigen is correlated with clinical staging according to the CDC. Thirty per cent of patients in the P2C category had a p24 antigen concentration >100 pg/ml and did poorly. Patients in P2B and P2D stage had the highest mean (SD) concentrations of p24 antigen, 202 (106) pg/ml and 204 (224) pg/ml , respectively. Tests for p24 antigen were more frequently positive in stages P2B, C, D, and E than in stages P2A or P2F.

Persistent antigenaemia was seen in 42

patients and 15 patients had intermittent antigenaemia. Patients with intermittent antigenaemia had a milder disease course, but most of those with persistent antigenaemia had a poor outcome. Only three patients with progressive disease did not have detectable serum antigen. Seventy per cent of patients with p24 antigen concentrations of >30 pg/ml eventually died or had severe disease within six to 12 months. Ten infants under 15 months with a p24 antigen concentration as low as 5 pg/ml did poorly.

Twenty of 50 patients (40%) had loss of p24 and or p17 antibody and all these patients had progressive disease. Conversion from ELISA positive for HIV to ELISA negative and/or a decreasing ELISA optical density was seen in 15 patients and this signalled a progressive disease course.

Discussion

HIV antigenaemia has been previously associated with symptomatic disease.⁴⁻¹⁰ Severe clinical manifestations were found to be closely related to raised concentrations of HIV p24 antigen in adults. Adults with symptomatic HIV infection had p24 antigen detected more frequently in the serum than asymptomatic adults.

In the present study we evaluated the presence of four HIV gene products in the serum of HIV infected children. The most common gene product was p17 in 62% of patients, followed by p24 (58%), gp120 (38%), and gp41 (18%). Three patients who were p24 antigen negative were p17 antigen positive. Using multiple antigens, the positive yield increased from 58% with p24 antigen alone to 72% utilising all four antigens. Thus an assay system detecting multiple antigens is potentially more useful than detecting p24 antigen alone. We also quantitated the HIV antigens by immunoblot and antigen capture assays and correlated them with disease course. The antibody profile of these patients was also examined.

By studying circulating immune complexes, CD4+ lymphocytes, HIV antigens, and HIV antibody by ELISA and western blot, three stages of HIV disease are apparent. They consist of an initial phase of absent or mild symptoms, a phase with symptoms, and an accelerated phase that precedes death. The results of laboratory tests depend on the stage at which the disease is studied.

In children in whom high concentrations of one or more HIV antigens were detectable in the serum, death followed within six to 24 months and was preceded by increasing HIV antigen concentration. Children who had low or undetectable serum HIV antigen remained stable or had mild symptoms (P2A). Seventy per cent of patients with a p24 antigen concentration >30 pg/ml had a poor outcome. This is in contrast to a previous report in which higher concentrations of p24 antigen denoted a poor prognosis.¹⁵ This may be due to the greater sensitivity of the DuPont antigen capture assay. The reason why 30% of patients with p24 antigen concentrations >30 pg/ml did not do poorly could be due to upregulation of HIV gene

Table 4 Correlation of serum p24 antigen with disease stage according to CDC classification

CDC stage	No of patients	p24 Antigen (pg/ml)*	Log p24 antigen (pg/ml)*
P2A	40	10.9 (2.09)	-58 (0.098)
P2B	20	202 (23.7)	2.25 (0.060)
P2C	35	71.2 (16.9)	1.42 (0.115)
P2D	44	204 (30.8)	2.00 (0.087)
P2E	5	27 (4.4)	1.40 (0.063)
P2F	20	32 (5.1)	1.16 (0.161)

p Value was <0.01 for P2B, C, D, and E v P2A; p value was <0.001 for P2C v P2B+P2D.

*Values are expressed as mean (SEM).

expression by infection¹⁸ and tumour necrosis factor.¹⁹ A decreasing antibody concentration as determined by ELISA or loss of p24 and p17 antibody was also indicative of progressive disease as seen in adults.²⁰ Thus monitoring of HIV antigen and antibody as well as concentrations of circulating immune complexes and CD4+ lymphocytes is of predictive value. Very high p24 antigen concentrations in isolation may not necessarily be predictive of a poor outcome as high values may be seen in association with other viral infections. Therefore, HIV infected children with a p24 antigen concentration >30 pg/ml and poor immune function need to be monitored more closely and treated aggressively. Infants under 1 year with any detectable antigen should also be treated aggressively and given prophylaxis for *P carinii* pneumonia. Other HIV antigens—p17, gp41, and gp120—in addition to p24 are of independent predictive value.

This study was supported by a grant from the National Institutes of Health (AI20671).

- 1 Quinnan GV, Siegel JP, Epstein JS. Mechanisms of T cell functional deficiency in the acquired immunodeficiency syndrome. *Ann Intern Med* 1985;104:710-4.
- 2 Klatzman D, Barre-Sinoussi F, Nageyre MT. Selective tropism of lymphadenopathy associated virus for helper inducer T lymphocytes. *Science* 1984;225:59-63.
- 3 Fauci AS, Macher AM, Longo DL. Acquired immunodeficiency syndrome: epidemiologic, clinical, immunologic and therapeutic considerations. *Ann Intern Med* 1984;100:96-106.
- 4 Wittek AE, Phelan MA, Well MA, et al. Detection of human immunodeficiency virus core protein in plasma by enzyme immunoassay. Association of antigenemia with symptomatic disease and T-helper cell depletion. *Ann Intern Med* 1987;107:286-92.
- 5 Pederson C, Nulsen CM, Vestergaard BF, Serstoft J. Temporal relation of antigenaemia and loss of antibodies to core antigens to development of clinical disease in HIV infection. *BMJ* 1987;295:567-69.
- 6 Lange JMA, Paul DA, Huisman HG. Persistent HIV antigenaemia and decline of HIV core antibodies associated with transition to AIDS. *BMJ* 1986;293:1459-62.
- 7 Lange JMA, Goudsmit J. Decline of antibody reactivity to HIV core protein is secondary to increased production of HIV antigen. *Lancet* 1987;ii:448.
- 8 Cao Y, Valentine F, Hojvat S. Detection of HIV antigen and specific antibodies to HIV core and envelope proteins in sera of patients with HIV infection. *Blood* 1987;70:575-8.
- 9 Lange JMA, Paul DA, de Wolf F. Viral gene expression, antibody patterns and immune complex formation in human immunodeficiency virus infection. *AIDS* 1987;1:15-20.
- 10 Goudsmit J, de Wolf F, Paul DA. Expression of human immunodeficiency virus antigen (HIV-Ag) in serum and cerebrospinal fluid during acute and chronic infection. *Lancet* 1986;ii:177-80.
- 11 de Wolf F, Goudsmit J, Paul DA. Risk of AIDS-related complex and AIDS in homosexual men with persistent HIV antigenaemia. *BMJ* 1987;295:513-6.
- 12 Blanche S, Le Deise F, Fischer A. Longitudinal study of 18 children with perinatal LAV/HTLV III infection: attempt at prognostic evaluation. *J Pediatr* 1986;109:965-70.
- 13 Epstein LG, Boucher CAB, Morrison SH. Persistent human immunodeficiency virus type I antigenemia in children correlates with disease progression. *Pediatrics* 1988;82:919-24.
- 14 Borkowsky W, Krasinsky K, Paul D. Human immunodeficiency virus infections in infants negative for anti-HIV by enzyme-linked immunoassay. *Lancet* 1987;ii:1168-71.
- 15 Borkowsky W, Krasinsky K, Paul D. Human immunodeficiency virus type I antigenemia in children. *J Pediatr* 1989;114:940-5.
- 16 Ellaurie M, Calvelli T, Rubinstein A. Reduction of HIV antigens following intravenous gammaglobulin in pediatric HIV infection. *Blood* 1987;70:119a.
- 17 Centers for Disease Control. Classification system for human immunodeficiency virus (HIV) infection in children under 13 years of age. *MMWR* 1987;36:225-36.
- 18 Mosca JD, Bednarik DP, Raj NBK, et al. Herpes simplex virus type-1 can reactivate transcription of latent human immunodeficiency virus. *Nature* 1987;325:67-70.
- 19 Okamoto T, Matsuyama T, Mori S, et al. Augmentation of HIV type-1 gene expression by tumor necrosis factor alpha. *AIDS Research and Human Retroviruses* 1989;5:131-8.
- 20 Lange JMA, de Wolf F, Krone WJA. Decline of antibody reactivity to outer viral core protein p17 is an earlier serological marker of disease progression in human immunodeficiency virus infection than anti-p24 decline. *AIDS* 1987;1:155-9.

Shigella seizures

Authors should get their title right if nothing else. My eyes were drawn to a paper headed 'Recurrent seizures in children with Shigella-associated convulsions (Lahat *et al*, *Annals of Neurology* 1990;28:393-5). Strange, I thought, I didn't know that convulsions with shigellosis were likely to recur. Well the point of the paper is to show that they aren't!

Fifty five children were followed up for between seven and 14 years. None had afebrile seizures and two had febrile convulsions in that time. Convulsions with shigella infection are different and do not carry the recurrence risk of febrile convulsions in general.

This paper opens up limitless possibilities for intriguing titles: 'Acrocephalopolysyndactyly in Prader-Willi syndrome'—it doesn't happen or 'Ochronosis following valproate therapy'—we've never seen it.

It could become a popular parlour game.

ARCHIVIST